GBP510

GBP510
Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of; administration	Intramuscular

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.[1][2][3][4][5]

It was jointly developed by the Institute for Protein Design of the University of Washington.[6][7]

The South Korean Ministry of Food and Drug Safety began the phase III clinical trial involving an estimated 3990 participants.[8][9][10]

References

"SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. Retrieved 28 July 2021.
"CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. Retrieved 28 July 2021.
"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
Moon-hee C (11 June 2021). "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. Retrieved 28 July 2021.
"Two nanoparticle vaccines enter clinical trials – Institute for Protein Design". Retrieved 18 August 2021.
"CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021.
"SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing".
"SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021.
SK Bioscience Co., Ltd. (14 October 2021). "A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations. Cite journal requires |journal= (help)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. Retrieved 28 July 2021.

[2] "CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. Retrieved 28 July 2021.

[3] "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.

[4] "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.

[5] Moon-hee C (11 June 2021). "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. Retrieved 28 July 2021.

[6] "Two nanoparticle vaccines enter clinical trials – Institute for Protein Design". Retrieved 18 August 2021.

[7] "CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021.

[8] "SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing".

[9] "SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021.

[10] SK Bioscience Co., Ltd. (14 October 2021). "A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations. Cite journal requires |journal= (help)